{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-022574","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.618637+00:00","generated_at":"2026-05-19T06:04:59.775578+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NAVIGATE trial: belapectin 2mg significantly reduces new varices in MASH cirrhosis patients","bullets":["In per-protocol, belapectin 2mg reduced new varices incidence at 18 months (p=0.04) vs placebo.","Liver stiffness measure improved -12.3% mean change for belapectin 2mg vs -3.1% for placebo.","Fewer subjects on belapectin showed worsening LSM >30% or >10 kPa (p=0.03 for 2mg, p=0.02 for 4mg).","Safety profile comparable to placebo: no drug-related SAEs, no DILI, similar discontinuation rates.","U.S. subgroup showed significant varices reduction with belapectin 2mg (p=0.02)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-022574","json":"https://secwatch.observer/filing/0001140361-25-022574.json","markdown":"https://secwatch.observer/filing/0001140361-25-022574.md","text":"https://secwatch.observer/filing/0001140361-25-022574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125022574/0001140361-25-022574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125022574/ef20050576_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:04:59.775578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}